Literature DB >> 12880941

Pindolol and the acceleration of the antidepressant response.

Per Plenge1, Erling T Mellerup.   

Abstract

BACKGROUND: It has been suggested that treatment with selective serotonin reuptake inhibitors (SSRIs) in combination with pindolol, a partial agonist at the 5-HT(1A) receptor, may produce a fast antidepressant response. However, inconsistent results have been obtained in clinical studies with combination of the two drugs. Some studies, most using paroxetine, show an acceleration of the antidepressant response, whereas studies with other SSRIs find no marked latency reduction.
METHODS: The free SSRI concentration in patients either receiving the first dose, or in steady state treatment with the five different SSRIs citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline was estimated using pharmacokinetic data for the individual drugs.
RESULTS: Due to differences between the drugs regarding protein binding, distribution volume and affinity for the 5-HT transporter (5-HTT), the 5-HT uptake inhibition obtained with clinically relevant doses differs markedly among the SSRIs.
CONCLUSIONS: A nearly complete blockade of the 5-HTT is obtained already after the first dose only with paroxetine, explaining why the latency reducing effect of pindolol preferentially is seen when pindolol is combined with paroxetine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880941     DOI: 10.1016/s0165-0327(02)00062-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; M Verhoye; J Van Audekerke; G Vanhoutte; Andrew S Lowe; Andrew M Blamire; Thomas Steckler; A Van der Linden; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

2.  Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT1A agonist.

Authors:  Li-Ming Zhang; Xiao-Yun Wang; Nan Zhao; Yu-Lu Wang; Xiao-Xu Hu; Yu-Hua Ran; Yan-Qin Liu; You-Zhi Zhang; Ri-Fang Yang; Yun-Feng Li
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

3.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

4.  Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.

Authors:  David H Overstreet; Joseph Hlavka; John P Feighner; Gabriela Nicolau; Jeffrey S Freed
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.